Skip to content

Motivation and Methylphenidate

Etude Comparative Monocentrique, randomisée, en Cross-over, en Double Aveugle, Contre Placebo, de l'Action du méthylphénidate Sur Les paramètres Cognitifs de la Motivation

Status
Completed
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03190681
Acronym
MBB_MPH
Enrollment
35
Registered
2017-06-19
Start date
2017-07-11
Completion date
2017-11-15
Last updated
2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Apathy, Impulsive Behavior, Motivation

Brief summary

The purpose of this study is to evaluate the impact of methylphenidate, a mixed dopaminergic and noradrenergic agent, onto the different components of motivation: decision-making, effort allocation and instrumental learning.

Interventions

DRUGRitalin (methylphenidate)10Mg Tablet

oral ingestion of 3 tablets in a single-dose

DRUGPlacebo Oral Tablet

oral ingestion of 3 tablets in a single-dose

Sponsors

Institut National de la Santé Et de la Recherche Médicale, France
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* weight\>= 50kg and \<=90kg * free and informed consent * social security affiliation * no chronic illness * no previous participation to a protocol wth similar tasks * no special legal status (guardianship,trusteeship) * no personnal or familial neurologic or psychiatric background * no contraceptive device for a reproductive woman

Exclusion criteria

* inability to squeeze a handgrip * smoking * psychoactive substance consumption less than 3 weeks ago * pregnant or breastfeeding woman * hypersensitivity to methylphenidate * hyperthyroidism * cardiovascular or cerebrovascular disease * respiratory, hepatic or renal failure * glaucoma * pheochromocytoma * gluten intolerance or hypersensitivity * galactosemia, glucose malabsorption syndrome, lactase deficit * countraindicated meds (IMAO, IMAO-A, orhtosympathomimetics, alcaloids, linezolin, enzymatic inducers, psycho-active drugs)

Design outcomes

Primary

MeasureTime frameDescription
coefficient of sensitivity to rewardtwo hours after administrationParameter characterizing the influence of reward expectation/experience onto behavior for each individual. This parameter is estimated through the fit of computational models to behaviors recorded in a battery of motivational tasks (choice task, effort task, Learning task).

Secondary

MeasureTime frameDescription
coefficient of sensitivity to efforttwo hours after administrationParameter characterizing the influence of effort expectation/experience onto behavior for each individual. This parameter is estimated through the fit of computational models to behaviors recorded in a battery of motivational tasks (choice task, effort task, Learning task).
coefficient of sensitivity to punishmenttwo hours after administrationParameter characterizing the influence of punishment expectation/experience onto behavior for each individual. This parameter is estimated through the fit of computational models to behaviors recorded in a battery of motivational tasks (choice task, effort task, Learning task).
coefficient of sensitivity to delaytwo hours after administrationParameter characterizing the influence of delay expectation onto behavior for each individual. This parameter is estimated through the fit of computational models to behaviors recorded in a battery of motivational tasks (choice task, effort task, Learning task).

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 25, 2026